MHRA approval for ATL1102 Phase IIb DMD clinical trial in UK
Filed with ASX · · 1 page · English
Percheron Therapeutics Limited on 6ix
Story so far
Earlier from Percheron Therapeutics
- First Patient Dosed in ATL1102 Phase IIb DMD Trial
- Chief Executive Officer and Managing Director Appointment
- PIIb DMD trial approved in Bulgaria- UK, Australia advancing
- Dosing commenced in the ATL1102 toxicology study
- Receipt of R&D Tax Incentive Payment
Later from Percheron Therapeutics
- Institutional Placement and proposed Share Purchase Plan SPP
- Quarterly Activities Report
- Intention to launch Share Purchase Plan
- Positive new DMD Combination Therapy Data in mdx mice
- Share Purchase Plan (SPP) Offer Booklet
Follow Percheron Therapeutics into a list and get an email when it puts out news.
Follow Percheron Therapeutics